- Frequency Therapeutics Inc FREQ announced clinical results from the Phase 2b study of FX-322 in individuals with acquired Sensorineural Hearing Loss (SNHL).
- The study, which enrolled 142 people with either sudden or noise-induced sensorineural hearing loss, failed to achieve its primary efficacy endpoint of improving speech perception.
- Data showed no statistically meaningful difference at day 90 between those administered FX-322 versus those receiving a placebo in the proportion of individuals that demonstrated an improvement in speech perception.
- No measurable improvements were observed in any of the study's secondary endpoints.
- The safety profile associated with FX-322 was favorable, and no study participants experienced a serious adverse event that was associated with treatment.
- Frequency Therapeutics will now discontinue the FX-322 development program. In addition, while dosing of FX-345, a second program to treat SNHL, has been completed in the initial safety cohort of an ongoing Phase 1b trial, that development program will also be discontinued.
- The company will now focus its resources on advancing its remyelination in the multiple sclerosis program in the clinic.
- It plans to begin its clinical program for remyelination in 1H 2024.
- FREQ will immediately reduce headcount as part of an overall restructuring, downsizing personnel by approximately 55%, extending its runway into 2025, and enabling it to complete the first clinical trial of its MS program in 2H 2024.
- It had cash, cash equivalents, and marketable securities of $83.1 million.
- Price Action: FREQ shares are down 80.2% at $0.78 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
